Gemtesa (Vibegron) for Overactive Bladder
Gemtesa (vibegron) is a highly selective beta-3 adrenergic agonist indicated for treating overactive bladder with symptoms of urgency, frequency, and urge urinary incontinence in adults, including men on BPH therapy, dosed at 75 mg once daily. 1
Indications
Gemtesa is FDA-approved for two specific populations 1:
- Adults with OAB: Treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency
- Men with OAB and BPH: Treatment of OAB symptoms in adult males already receiving pharmacological therapy for benign prostatic hyperplasia
The 2024 AUA/SUFU guidelines strongly recommend offering beta-3 agonists (like vibegron) or antimuscarinics to patients with OAB, with Grade A evidence supporting their efficacy in improving urgency, frequency, and urgency urinary incontinence 2. Notably, beta-3 agonists are typically preferred before antimuscarinics due to concerns about dementia and cognitive impairment associated with chronic antimuscarinic use 2.
Recommended Dose
The recommended dose is 75 mg orally once daily 1. Key administration details:
- Swallow tablet whole with water
- May be crushed and mixed with applesauce if swallowing difficulties exist
- Single daily dosing improves compliance compared to multiple-daily-dose regimens
Contraindications
Do not use Gemtesa in patients with prior hypersensitivity reactions to vibegron or any product components 1. This is the only absolute contraindication listed in the FDA label.
Important Precautions (Not Absolute Contraindications)
- Not recommended in end-stage renal disease with or without hemodialysis 1
- Not recommended in severe hepatic impairment 1
- Monitor carefully for urinary retention, especially in patients with bladder outlet obstruction or those taking concurrent antimuscarinic medications 1
Common Adverse Effects
The most common adverse reactions (≥2% incidence) reported with Gemtesa are 1:
- Headache
- Urinary tract infection
- Nasopharyngitis
- Diarrhea
- Nausea
- Upper respiratory tract infection
Vibegron demonstrates a favorable safety profile with significantly lower rates of dry mouth compared to antimuscarinics 3, 4. In the pivotal EMPOWUR trial, only 1.7% of vibegron-treated patients discontinued due to adverse events versus 3.3% with tolterodine 3. The 52-week extension study confirmed sustained tolerability with dry mouth occurring in only 1.8% of vibegron patients versus 5.2% with tolterodine 4.
Serious Adverse Effects to Monitor
- Angioedema: Angioedema of the face and/or larynx has been reported 1
- Urinary retention: Risk is elevated in patients with bladder outlet obstruction or concurrent antimuscarinic use; discontinue if retention develops 1
- Hypertension: Incidence was 1.7% (same as placebo in trials), but measure serum digoxin concentrations before initiating and monitor if patient is on digoxin 1, 3
Clinical Efficacy Highlights
Vibegron demonstrates rapid onset of action with significant improvements as early as week 2 3. In the EMPOWUR trial, vibegron reduced:
- Micturitions by 1.8 episodes/day (vs 1.3 for placebo, p<0.001)
- Urge incontinence episodes by 2.0/day (vs 1.4 for placebo, p<0.0001)
- Urgency episodes significantly (p<0.01)
- Increased volume per micturition 3
Among incontinent patients, 61% achieved ≥75% reduction in urge incontinence episodes at 52 weeks, and 40.8% achieved complete dryness 4.
Key Advantages Over Alternatives
Vibegron's high beta-3 receptor selectivity provides distinct advantages: no cytochrome P450 interactions (unlike mirabegron), minimal cardiovascular effects, and no anticholinergic burden 5, 6. This makes it particularly valuable for:
- Older adults with polypharmacy concerns
- Patients at risk for cognitive impairment (avoiding antimuscarinic-associated dementia risk)
- Men with BPH on alpha-blockers (proven safe and effective in COURAGE trial) 7
Common Pitfalls to Avoid
- Do not combine with antimuscarinics initially without careful monitoring for urinary retention, especially in men with BPH or bladder outlet obstruction
- Do not prescribe in end-stage renal disease or severe hepatic impairment
- Monitor digoxin levels if patient is on concurrent digoxin therapy 1
- Counsel patients that this requires long-term compliance for sustained benefit, per guideline recommendations 2